STOCK TITAN

Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

Axogen (NASDAQ: AXGN) reported Q3 2024 financial results with revenue of $48.6 million, up 17.9% year-over-year. Gross margin decreased to 74.9% from 76.8% in Q3 2023. Net loss improved to $1.9 million ($0.04 per share) compared to $4.1 million ($0.10 per share) last year. Adjusted EBITDA reached $6.5 million, up from $2.4 million in Q3 2023.

The FDA accepted the company's Biologics License Application for Avance Nerve Graft with a PDUFA date of September 5th, 2025. Axogen maintains full-year revenue guidance of $182-186 million and expects to be at the high end of its 74-76% gross margin range.

Axogen (NASDAQ: AXGN) ha riportato i risultati finanziari del terzo trimestre 2024 con un fatturato di 48,6 milioni di dollari, in aumento del 17,9% rispetto all'anno precedente. Il margine lordo è diminuito al 74,9% rispetto al 76,8% del terzo trimestre 2023. La perdita netta è migliorata a 1,9 milioni di dollari (0,04 dollari per azione) rispetto ai 4,1 milioni di dollari (0,10 dollari per azione) dello scorso anno. EBITDA Rettificato ha raggiunto 6,5 milioni di dollari, in aumento rispetto ai 2,4 milioni di dollari del terzo trimestre 2023.

La FDA ha accettato la domanda di licenza biologica dell'azienda per il trapianto di nervo Avance, con una data PDUFA fissata per il 5 settembre 2025. Axogen mantiene la guida sul fatturato annuale compreso tra 182 e 186 milioni di dollari e si aspetta di essere nella parte alta della sua fascia di margine lordo del 74-76%.

Axogen (NASDAQ: AXGN) reportó los resultados financieros del tercer trimestre de 2024 con ingresos de 48,6 millones de dólares, un aumento del 17,9% en comparación con el año anterior. El margen bruto disminuyó al 74,9% desde el 76,8% en el tercer trimestre de 2023. La pérdida neta mejoró a 1,9 millones de dólares (0,04 dólares por acción) en comparación con 4,1 millones de dólares (0,10 dólares por acción) el año pasado. EBITDA Ajustado alcanzó los 6,5 millones de dólares, frente a los 2,4 millones de dólares en el tercer trimestre de 2023.

La FDA aceptó la Solicitud de Licencia Biológica de la compañía para el Injerto de Nervio Avance, con una fecha PDUFA del 5 de septiembre de 2025. Axogen mantiene una guía de ingresos anuales de 182 a 186 millones de dólares y espera estar en la parte alta de su rango de margen bruto del 74-76%.

Axogen (NASDAQ: AXGN)은 2024년 3분기 재무 결과를 보고하며 매출이 4,860만 달러로 작년 대비 17.9% 증가했다고 밝혔습니다. 총 이익률은 2023년 3분기의 76.8%에서 74.9%로 감소했습니다. 순손실은 190만 달러(주당 0.04달러)로 개선되어 작년의 410만 달러(주당 0.10달러)보다 나아졌습니다. 조정 EBITDA는 620만 달러에 도달하여 2023년 3분기의 240만 달러에서 증가했습니다.

FDA는 Avance 신경 이식에 대한 회사의 생물학적 면허 신청서를 수리했으며 PDUFA 날짜는 2025년 9월 5일입니다. Axogen은 연간 매출 가이드를 1억 8,200만에서 1억 8,600만 달러로 유지하며, 74-76%의 총 이익률 범위 상단에 이를 것으로 기대하고 있습니다.

Axogen (NASDAQ: AXGN) a publié ses résultats financiers pour le troisième trimestre 2024, avec un chiffre d'affaires de 48,6 millions de dollars, en hausse de 17,9% par rapport à l'année précédente. La marge brute a diminué à 74,9% contre 76,8% au troisième trimestre 2023. La perte nette s'est améliorée à 1,9 million de dollars (0,04 dollar par action) comparé à 4,1 millions de dollars (0,10 dollar par action) l'année dernière. EBITDA Ajusté a atteint 6,5 millions de dollars, en hausse par rapport à 2,4 millions de dollars au troisième trimestre 2023.

La FDA a accepté la demande de licence biologique de la société pour le Greffon Nerveux Avance, avec une date PDUFA fixée au 5 septembre 2025. Axogen maintient ses prévisions de chiffre d'affaires annuel entre 182 et 186 millions de dollars et s'attend à se situer à la limite supérieure de sa fourchette de marge brute de 74-76%.

Axogen (NASDAQ: AXGN) hat die finanziellen Ergebnisse für das 3. Quartal 2024 veröffentlicht, mit einem Umsatz von 48,6 Millionen Dollar, was einem Anstieg von 17,9% im Vergleich zum Vorjahr entspricht. Die Bruttomarge sank von 76,8% im 3. Quartal 2023 auf 74,9%. Der Nettverlust verbesserte sich auf 1,9 Millionen Dollar (0,04 Dollar pro Aktie) im Vergleich zu 4,1 Millionen Dollar (0,10 Dollar pro Aktie) im letzten Jahr. Bereinigtes EBITDA erreichte 6,5 Millionen Dollar, ein Anstieg von 2,4 Millionen Dollar im 3. Quartal 2023.

Die FDA hat den Antrag auf biologischen Lizenz für das Avance Nerventransplantat angenommen, mit einem PDUFA-Datum vom 5. September 2025. Axogen hält die Jahresumsatzprognose von 182 bis 186 Millionen Dollar aufrecht und erwartet, am oberen Ende seiner Bruttomargenbandbreite von 74-76% zu liegen.

Positive
  • Revenue increased 17.9% YoY to $48.6 million
  • Net loss improved by 53.7% to $1.9 million
  • Adjusted EBITDA grew significantly to $6.5 million from $2.4 million YoY
  • Cash position improved to $30.5 million from $27.1 million in Q2 2024
  • FDA accepted BLA filing for Avance Nerve Graft
Negative
  • Gross margin declined to 74.9% from 76.8% YoY
  • Company still operating at a net loss of $1.9 million

Insights

A strong quarter for Axogen with notable improvements across key metrics. $48.6M revenue represents a robust 17.9% YoY growth, while net loss narrowed significantly to $1.9M from $4.1M. The shift to adjusted net income of $3.1M and improved adjusted EBITDA of $6.5M signals strengthening operational efficiency.

The cash position improvement to $30.5M from $27.1M QoQ demonstrates solid working capital management. While gross margin declined slightly to 74.9%, the company expects to hit the higher end of their 74-76% annual target. The maintained revenue guidance of $182-186M with expected positive cash flow shows management's confidence in sustained growth trajectory.

The FDA's acceptance of the BLA filing for Avance Nerve Graft with a PDUFA date of September 5th, 2025, marks a important regulatory milestone. The FDA's decision not to require an advisory committee meeting suggests confidence in the submission package. Novel data presented at ASSH highlighting nerve damage patterns and repair solutions strengthens the clinical positioning of their products.

The National Resensation Breast program launch alongside regional surgeon education initiatives in Extremities and Head & Neck demonstrates strategic focus on expanding market penetration through physician education and awareness. These efforts are critical for establishing nerve repair as a standard of care globally.

ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024.

Third Quarter Financial Results

  • Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.
  • In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% in the third quarter of 2023.
  • Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $4.1 million, or $0.10 per share in the third quarter of 2023.
  • Adjusted net income for the quarter was $3.1 million, or $0.07 per share, compared to adjusted net loss of $0.7 million, or $0.01 per share, in the third quarter of 2023.
  • Adjusted EBITDA was $6.5 million for the quarter, compared to an adjusted EBITDA of $2.4 million in the third quarter of 2023.
  • The balance of all cash, cash equivalents, and investments on September 30, 2024, was $30.5 million, as compared to a balance of $27.1 million on June 30, 2024

“We are pleased with the third quarter’s topline revenue and EBITDA growth. Notably, our revenue performance in the quarter was broad based across our entire portfolio of nerve repair and protection applications, reflecting improved sales productivity and commercial execution,” commented Michael Dale, CEO and Director of Axogen, Inc. “Since joining the Axogen team, everything I’ve observed and experienced reaffirms my estimation that we have significant undeveloped potential to make nerve repair an expected standard of care around the world.”

Summary of Business Highlights

  • On November 1st, the U.S. Food and Drug Administration (FDA) notified the company that they accepted the filing of its Biologics License Application (BLA) for Avance Nerve Graft® under a standard review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 5th, 2025. The FDA further indicated that it does not currently plan to hold an advisory committee for the application.
  • During the quarter, at the American Society for Surgery of the Hand (ASSH), we presented novel data highlighting the extent of nerve damage that occurs in common injuries, the importance of protection of the nerve coaptation site and the growing role of Avance Nerve Graft in sensory, mixed and motor nerve repair.
  • Recently, we executed on a National Resensation Breast program as well as numerous regional surgeon education programs in Extremities and Head & Neck.

2024 Financial Guidance

We are maintaining our full year revenue guidance in the range of $182 million to $186 million, and now expect to be at the high end of our 74-76% full year gross margin range. Additionally, we reiterate that we expect to be net cash flow positive cumulatively for the period from April 1st through year end.

Conference Call

The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the Company's website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the Company's website at www.axogeninc.com under Investors.

About Axogen

Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products used across various applications and surgical specialties, including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and the surgical treatment of pain. These applications encompass both scheduled and emergent procedures. Specifically, scheduled procedures are often pursued by patients seeking relief from conditions caused by a nerve defect or previous surgical interventions. Such procedures include providing sensation for women undergoing breast reconstruction following a mastectomy, nerve reconstruction after the surgical removal of painful neuromas, and oral and maxillofacial procedures, as well as nerve decompression. Conversely, emergent procedures typically arise from injuries that initially present in an emergency room, with specialists intervening either immediately or within a few days following the initial injury. This broad range of applications underscores Axogen’s vital role in addressing diverse patient needs in peripheral nerve repair.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; Avive+ Soft Tissue Matrix TM, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

For more information, visit www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements

This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the estimation of significant undeveloped potential to make nerve repair an expected standard of care around the world, the Company's expectations regarding the potential for approval of the BLA in September 2025, as well as statements under the subheading “2024 Financial Guidance.” Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, global supply chain issues, hospital staffing issues, product development, product potential, clinical outcomes, regulatory process and approvals, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, global business disruption caused by Russia’s invasion of Ukraine and related sanctions, recent geopolitical conflicts in the Middle East, potential disruptions due to management transitions, as well as those risk factors described under Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the most recently ended fiscal year and in our subsequent Quarterly Reports on Form 10Q. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense and litigation and related expenses. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Common Share - basic and diluted which excludes non-cash stock compensation expense and litigation and related expenses from Net Loss and Net Loss Per Common Share - basic and diluted, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements.

Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com


​AXOGEN, INC.
Condensed Consolidated Balance Sheets
(unaudited)
(In thousands, except share and per share amounts)

September 30,
2024
 December 31,
2023
Assets  
Current assets:  
Cash and cash equivalents$18,662  $31,024 
Restricted cash 6,000   6,002 
Investments 5,868    
Accounts receivable, net of allowance for doubtful accounts of $888 and $337, respectively 24,629   25,147 
Inventory, net 29,363   23,020 
Prepaid expenses and other 1,730   2,811 
Total current assets 86,252   88,004 
Property and equipment, net 85,632   88,730 
Operating lease right-of-use assets 14,886   15,562 
Intangible assets, net 5,215   4,531 
Total assets$191,985  $196,827 
   
Liabilities and shareholders’ equity   
Current liabilities:   
Accounts payable and accrued expenses$21,177  $28,883 
Current maturities of long-term lease obligations 1,856   1,547 
Total current liabilities 23,033   30,430 
   
Long-term debt, net of debt discount and financing fees 47,272   46,603 
Long-term lease obligations 19,734   21,142 
Debt derivative liabilities 2,445   2,987 
Other long-term liabilities 94    
Total liabilities 92,578   101,162 
   
Commitments and contingencies - see Note 12   
   
Shareholders’ equity:   
Common stock, $0.01 par value per share; 100,000,000 shares authorized; 44,002,323 and 43,124,496 shares issued and outstanding 440   431 
Additional paid-in capital 390,677   376,530 
Accumulated deficit (291,710)  (281,296)
Total shareholders’ equity 99,407   95,665 
Total liabilities and shareholders’ equity$191,985   196,827 
 

AXOGEN, INC.
Condensed Consolidated Statements of Operations
(unaudited)
(In thousands, Except share and per share amounts)

 Three Months Ended Nine Months Ended
 September
30, 2024
 September
30, 2023
 September
30, 2024
 September
30, 2023
      
Revenues $48,644  $41,271  $137,933  $116,090 
Cost of goods sold  12,206   9,567   33,531   26,242 
Gross profit  36,438   31,704   104,402   89,848 
Costs and expenses:        
Sales and marketing  18,924   19,165   58,437   57,471 
Research and development  6,996   6,694   21,063   20,164 
General and administrative  10,834   9,870   30,206   30,481 
Total costs and expenses  36,754   35,729   109,706   108,116 
Loss from operations  (316)  (4,025)  (5,304)  (18,268)
Other income (expense):        
Investment income  296   367   816   1,151 
Rental income  90      90    
Interest expense  (1,893)  (827)  (6,405)  (992)
Change in fair value of derivatives  13   402   542   649 
Other expense  (48)  (6)  (153)  (363)
Total other (expense) income, net  (1,542)  (64)  (5,110)  445 
Net loss $(1,858) $(4,089) $(10,414) $(17,823)
         
Weighted average common shares outstanding — basic and diluted  43,882,110   43,022,328   43,610,481   42,821,284 
Loss per common share — basic and diluted $(0.04) $(0.10) $(0.24) $(0.42)
 

AXOGEN INC.
RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES
(unaudited)
(In thousands, except per share amounts)

  Three Months Ended Nine Months Ended
  September
30, 2024
 September
30, 2023
 September
30, 2024
 September
30, 2023
         
Net loss $(1,858) $(4,089) $(10,414) $(17,823)
Depreciation and amortization expense  1,719   1,224   5,034   2,874 
Investment income  (296)  (367)  (816)  (1,151)
Income tax expense  26   12   76   331 
Interest expense  1,893   827   6,405   992 
EBITDA - non GAAP $1,484  $(2,393) $285  $(14,777)
         
Non cash stock-based compensation expense $5,004  $4,747  $12,830  $13,091 
Adjusted EBITDA - non GAAP $6,488  $2,354  $13,115  $(1,686)
         
Net loss $(1,858) $(4,089) $(10,414) $(17,823)
Non cash stock-based compensation expense  5,004   4,747   12,830   13,091 
Adjusted net income (loss) - non GAAP $3,146  $658  $2,416  $(4,732)
         
Weighted average common shares outstanding basic and diluted   43,882,110   43,022,328   43,610,481   42,821,284 
         
Loss per common share — basic and diluted $(0.04) $(0.10) $(0.24) $(0.42)
Non cash stock-based compensation expense $0.11  $0.11  $0.29  $0.31 
Adjusted net income (loss) per common share - basis and diluted - non GAAP $0.07  $0.01  $0.05  $(0.11)
 

AXOGEN, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(unaudited)
(In thousands, except per share)

Common Stock Additional
Paid-in

Capital
 Accumulated
Deficit
 Total
Shareholders'

Equity
Shares 
Amount
   
Three Months Ended September 30, 2024         
Balance at June 30, 202443,824,738 $438 $385,101  $(289,852)  95,687 
Net loss       (1,858)  (1,858)
Stock-based compensation    5,004      5,004 
Issuance of restricted and performance stock units112,185  1  (1)      
Exercise of stock options and employee stock purchase plan65,400  1  573      574 
Balance at September 30, 202444,002,323 $440 $390,677  $(291,710)  99,407 
    
Nine Months Ended September 30, 2024    
Balance at December 31, 202343,124,496 $431 $376,530  $(281,296) $95,665,197 
Net loss       (10,414)  (10,414)
Stock-based compensation    12,830      12,830 
Issuance of restricted and performance stock units695,571  7  (7)      
Exercise of stock options and employee stock purchase plan182,256  2  1,324      1,326 
Balance at September 30, 202444,002,323 $440 $390,677  $(291,710) $99,407 
          
Three Months Ended September 30, 2023         
Balance at June 30, 202342,979,541 $430 $370,036  $(273,314)  97,152 
Net loss       (4,089)  (4,089)
Stock-based compensation    4,747      4,747 
Issuance of restricted and performance stock units59,858           
Exercise of stock options and employee stock purchase plan           
Balance at September 30, 202343,039,399 $430 $374,783  $(277,403) $97,810 
          
Nine Months Ended September 30, 2023         
Balance at December 31, 202242,445,517 $424 $360,155  $(259,580) $100,999 
Net loss       (17,823)  (17,823)
Stock-based compensation    13,091      13,091 
Issuance of restricted and performance stock units356,236  4  (4)      
Exercise of stock options and employee stock purchase plan237,646  2  1,541      1,543 
Balance at September 30, 202343,039,399 $430 $374,783  $(277,403) $97,810 
 


AXOGEN, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)

Nine Months Ended
September 30, 2024 September 30, 2023
Cash flows from operating activities:  
Net loss$(10,414) $(17,823)
Adjustments to reconcile net loss to net cash used in operating activities:   
Depreciation 4,831   2,660 
Amortization of right-of-use assets 889   826 
Amortization of intangible assets 202   214 
Amortization of debt discount and deferred financing fees 669   666 
Provision for (recovery of) bad debt 604   (311)
Change in fair value of derivatives (542)  (649)
Investment (gains) loss (95)  (660)
Share-based compensation 12,830   13,091 
Change in operating assets and liabilities:   
Accounts receivable (85)  (766)
Inventory (6,343)  (4,114)
Prepaid expenses and other 1,189   (623)
Accounts payable and accrued expenses (7,125)  3,012 
Operating lease obligations (1,303)  (1,012)
Cash paid for interest portion of finance leases (2)  (2)
Other liabilities 495   (14)
Net cash used in operating activities$(4,200) $(5,505)
  
Cash flows from investing activities:  
Purchase of property and equipment$(2,431) $(12,409)
Purchase of investments (5,773)  (10,203)
Proceeds from sale of investments    42,874 
Cash payments for intangible assets (1,280)  (732)
Net cash (used in) provided by investing activities$(9,484) $19,530 
  
Cash flows from financing activities:  
Cash paid for debt portion of finance leases$(6) $(7)
Proceeds from exercise of stock options and ESPP stock purchases 1,326   1,543 
Net cash provided by financing activities$1,320  $1,536 
Net (decrease) increase in cash, cash equivalents, and restricted cash (12,364)  15,561 
Cash, cash equivalents, and restricted cash, beginning of period 37,026   21,535 
Cash, cash equivalents, and restricted cash, end of period$24,662  $37,096 
 

FAQ

What was Axogen's (AXGN) revenue growth in Q3 2024?

Axogen reported Q3 2024 revenue of $48.6 million, representing a 17.9% increase compared to Q3 2023.

When is the PDUFA date for Axogen's (AXGN) Avance Nerve Graft?

The FDA assigned a PDUFA goal date of September 5th, 2025 for Axogen's Avance Nerve Graft BLA review.

What is Axogen's (AXGN) revenue guidance for 2024?

Axogen maintains its full-year 2024 revenue guidance in the range of $182 million to $186 million.

What was Axogen's (AXGN) Q3 2024 gross margin?

Axogen's gross margin in Q3 2024 was 74.9%, down from 76.8% in Q3 2023.

Axogen, Inc.

NASDAQ:AXGN

AXGN Rankings

AXGN Latest News

AXGN Stock Data

587.95M
41.56M
5.55%
84.61%
2.57%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ALACHUA